Envonatide Phase III NSCLC Trial Completes Patient Enrollment on May 22

GateNews
On May 22, Xianshen Zaiming, a subsidiary of Xianshen Pharma, announced that its Phase III randomized, controlled, double-blind, multicenter trial of envonatide injection for neoadjuvant and adjuvant treatment of resectable non-small cell lung cancer (NSCLC) has completed enrollment of all study participants. The study was conducted in collaboration with Siluodi Pharma and Cann Biopharma.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments